Baxter International Inc
XMUN:BTL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Baxter International Inc
XMUN:BTL
|
US |
|
R
|
Rithm Capital Corp
SWB:14N1
|
US |
Baxter International Inc
Baxter International makes medical products that hospitals and other care providers use to treat patients every day. Its lineup includes IV fluids, infusion pumps, drug-delivery systems, nutrition therapies, and disposable supplies that help doctors and nurses give medicines, fluids, and nutrition safely and consistently. Its main customers are hospitals, outpatient clinics, dialysis and other specialty care providers, and home-care settings that need reliable medical equipment and consumables. Baxter makes money by selling equipment, recurring disposable items, and service or maintenance support for the devices it installs. What makes Baxter different is that it sits in the middle of patient care, not as a drug maker but as a supplier of the tools and supplies clinicians use to deliver treatment. That gives the company a mix of one-time equipment sales and steadier repeat business from products that must be replaced and replenished over time.
Baxter International makes medical products that hospitals and other care providers use to treat patients every day. Its lineup includes IV fluids, infusion pumps, drug-delivery systems, nutrition therapies, and disposable supplies that help doctors and nurses give medicines, fluids, and nutrition safely and consistently.
Its main customers are hospitals, outpatient clinics, dialysis and other specialty care providers, and home-care settings that need reliable medical equipment and consumables. Baxter makes money by selling equipment, recurring disposable items, and service or maintenance support for the devices it installs.
What makes Baxter different is that it sits in the middle of patient care, not as a drug maker but as a supplier of the tools and supplies clinicians use to deliver treatment. That gives the company a mix of one-time equipment sales and steadier repeat business from products that must be replaced and replenished over time.
Quarter in line: Baxter said first quarter results were in line with expectations, with sales of $2.7 billion, up 3% reported and down 1% organically, and adjusted EPS of $0.36 versus $0.55 a year ago.
Guidance reaffirmed: Management reiterated full-year 2026 guidance, still expecting flat to 1% reported sales growth and adjusted EPS of $1.85 to $2.05.
First-half pressure: The company expects the first half of 2026 to remain pressured by Novum-related issues, tariffs, and higher manufacturing costs, with improvement expected in the second half.
Novum risk remains: Baxter did not see a material impact from Novum returns in Q1, but it is still baking in the possibility of customer returns and a continued shipment and installation hold for the full year.
Balance sheet focus: Free cash flow improved to $76 million from negative $221 million a year ago, and Baxter reiterated its goal of net leverage around 3x by the end of 2026.
Turnaround progress: Management highlighted progress from the Baxter GPS operating system, more than 230 continuous improvement events in Q1, and early traction in cost control, service reliability, and execution.
